Cancer Research Versailles No Abst  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasaki, C. Y.
Right arrow Articles by Longo, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, C. Y.
Right arrow Articles by Longo, D. L.
[Cancer Research 60, 7057-7065, December 15, 2000]
© 2000 American Association for Cancer Research


Tumor Biology

Truncation of the Extracellular Region Abrogrates Cell Contact but Retains the Growth-suppressive Activity of E-cadherin

Carl Y. Sasaki1, Hsingchi Lin, Patrice J. Morin and Dan L. Longo

Laboratories of Immunology [C. Y. S., D. L. L.] and Biological Chemistry [H. L., P. J. M.], National Institute on Aging, NIH, Baltimore, Maryland 21224

E-cadherin has been demonstrated to induce growth suppression and decrease the invasiveness of cancer cells and thus has been proposed to be a tumor suppressor gene. The ability of E-cadherin to mediate cell-cell contact and contact inhibition presumably accounts for its antitumor effects, which are attributed to the extracellular domain of the protein. Here we report that blocking the ability of E-cadherin to mediate contact inhibition by either antagonistic antibodies or expression of a mutant form of E-cadherin with the extracellular region deleted does not abrogate growth suppression. Transfection of the E-cadheringene into the human prostate cancer cell line TSU.Pr-1 induced cell-cell contact formation, growth suppression, and redistribution of ß-catenin to the cell membrane. Treatment of the E-cadherin transfectant (CAD) with blocking antibodies disrupted cell-cell contact formation but did not influence the growth rate, suggesting that cell-cell interaction is not required for E-cadherin-mediated growth suppression. Similarly, transfection of an E-cadherin construct in which the NH2-terminal (extracellular) region was deleted did not allow cell-cell contact formation but induced growth suppression. In contrast, transfection of an E-cadherin construct in which the COOH-terminal (cytoplasmic) region was deleted did not induce suppression but promoted cell contact formation. In cells expressing E-cadherin lacking the cytoplasmic region, ß-catenin was evenly distributed in the cytoplasm. By contrast, in cells expressing E-cadherin lacking the extracellular region, ß-catenin was cell membrane associated. Growth suppression was always associated with the localization of ß-catenin to the cell membrane. The redistribution of ß-catenin from the cytoplasm to the cell membrane initially suggested the involvement of the Wnt signaling pathway in regulating cell growth. However, only small differences in ß-catenin/T-cell factor signaling were detected in control and E-cadherin-expressing cells, suggesting that the Wnt pathway is not involved. Taken together, these findings suggest that E-cadherin-induced growth inhibition may not be solely attributed to contact inhibition but may involve the redistribution of ß-catenin from the cytoplasm to the cell membrane, and this redistribution may affect growth pathways independent of T-cell factor.




This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
X.-Q. Wang, H. Li, V. Van Putten, R. A. Winn, L. E. Heasley, and R. A. Nemenoff
Oncogenic K-Ras Regulates Proliferation and Cell Junctions in Lung Epithelial Cells through Induction of Cyclooxygenase-2 and Activation of Metalloproteinase-9
Mol. Biol. Cell, February 1, 2009; 20(3): 791 - 800.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Toyoshima, N. Tanaka, J. Aoki, Y. Tanaka, K. Murata, M. Kyuuma, H. Kobayashi, N. Ishii, N. Yaegashi, and K. Sugamura
Inhibition of Tumor Growth and Metastasis by Depletion of Vesicular Sorting Protein Hrs: Its Regulatory Role on E-Cadherin and {beta}-Catenin
Cancer Res., June 1, 2007; 67(11): 5162 - 5171.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Verras, J. Brown, X. Li, R. Nusse, and Z. Sun
Wnt3a Growth Factor Induces Androgen Receptor-Mediated Transcription and Enhances Cell Growth in Human Prostate Cancer Cells
Cancer Res., December 15, 2004; 64(24): 8860 - 8866.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
A. S.T. Wong and B. M. Gumbiner
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin
J. Cell Biol., June 23, 2003; 161(6): 1191 - 1203.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z.-y. Huang, Y. Wu, N. Hedrick, and D. H. Gutmann
T-Cadherin-Mediated Cell Growth Regulation Involves G2 Phase Arrest and Requires p21CIP1/WAF1 Expression
Mol. Cell. Biol., January 15, 2003; 23(2): 566 - 578.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Yang, X. Li, M. Sharma, C. Y. Sasaki, D. L. Longo, B. Lim, and Z. Sun
Linking beta -Catenin to Androgen-signaling Pathway
J. Biol. Chem., March 22, 2002; 277(13): 11336 - 11344.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.